Pfizer’s Plans To Market Accupril As A “Branded Generic” Challenged By Teva

Pfizer intends to sell generic quinapril through its Greenstone subsidiary as soon as Teva triggers its own 180-day marketing exclusivity for the ACE inhibitor, Teva’s citizen petition to FDA states. Teva asserts Pfizer should be required to file a preapproval supplemental NDA before marketing the generic.